Ensysce Biosciences (NASDAQ:ENSC) released its 4Q2024 results that showed a good cash balance of $3.5 million due in large part to the financing activities management has undertaken which we’ve ...
Ensysce Biosciences (ENSC) will host a symposium on Wednesday, September 3, 2025, during PAINWeek 2025, designed to share perspectives with ...
SAN DIEGO, CA / ACCESS Newswire / March 5, 2025 /Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company developing innovative solutions for ...
Analgesic Experts Consider Pain Indications Versus New Classes of Analgesics ~ ~ Panel Discussion Posted to Ensysce's Corporate Website ~ SAN DIEGO, CA / ACCESS Newswire / March 18, 2025 /Ensysce ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback